Antibody subsets are mapped to distinct clinical trajectories: anti-TIF1-γ and anti-NXP2 are associated with malignancy, while anti-MDA5 is associated with vasculopathic skin disease and rapidly progressive interstitial lung disease, particularly in amyopathic or hypomyopathic presentations. This evidence concerns the gene IFIH1 and interstitial lung disease.